What We're Reading: Page 314
Industry reads hand-picked by our editors
Dec 19, 2016
-
Los Angeles Times
OxyContin goes global - 'We're only just getting started'
-
Reuters
AstraZeneca oncology head jumps ship to become Innate CEO
-
The Wall Street Journal
Hospitals alter routines to control drug spending
-
Bloomberg
Gilead's patent loss to Merck started with a broken friendship
Dec 16, 2016
-
Bloomberg
Stem cells may be the next frontier for diabetes drugmaker Novo
-
The Economist
A new type of molecular medicine may be needed to halt cancers
-
Reuters
India's Aurobindo shares hit nine-month low on US price-fixing lawsuit
-
Life Sci VC
Positive impact of external sourcing on pharma R&D productivity
Dec 15, 2016
-
The Boston Globe
A new moniker and more cash for Flagship Ventures
-
CNBC
Pfizer gets letter from US senators seek information on drug to treat opioid overdoses
-
MIT Technology Review
Google’s long, strange life span trip
-
San Francisco Business Times
Meet Genentech's new CEO as Ian Clark exits for retirement
Dec 14, 2016
Dec 13, 2016
Dec 12, 2016
-
The Economist
High price tags for new medicines are about to come under renewed pressure
-
Fortune
Big pharma just had a terrible, horrible, no good, very bad week of job cuts
-
The New York Times
Lives and profits in the balance: The high stakes of medical patents
-
MIT Technology Review
The Cancer Lottery
Previous
